

## **Grifols and IrsiCaixa join forces to promote biomedical research on HIV and associated diseases**

- In alignment with its ongoing commitment to innovation, Grifols will contribute EUR 1.5 million every year for 5 years through the Grifols Innovation and New Technologies Office.
- These resources will be allocated to finance leading-edge research lines to search for new treatments for HIV/AIDS and associated diseases, as well as to address other core biomedical challenges by leveraging IrsiCaixa's broad scientific expertise.
- This collaboration makes Grifols, together with the "la Caixa" Banking Foundation, a preferential partner to finance IrsiCaixa's research lines. Additionally, the accord grants Grifols preference to exploit the results and patents stemming from IrsiCaixa's diverse research initiatives, while IrsiCaixa will retain exclusive ownership.
- IrsiCaixa AIDS Research Institute was created as a private non-profit foundation in 1995 by "la Caixa" Banking Foundation and the Catalanian Government Ministry of Health to promote research aimed at eradicating HIV/AIDS and associated diseases.
- This morning, Albert Barberà, General Manager of Research and Innovation in Health of the Ministry of Health of the Government of Catalonia; Josep Vilarasau, Honorary Chairman of "la Caixa" Banking Foundation; Àngel Font, Corporate Director of Research & Strategy of "la Caixa" Banking Foundation; Bonaventura Clotet, Director of IrsiCaixa; Raimon Grifols and Víctor Grifols, CEOs of Grifols, have formalised the agreement in CosmoCaixa.

**Barcelona, April 6, 2018.-** Grifols, (MCE:GRF, MCE:GRF.P y NASDAQ:GRFS), one of the top three worldwide producers of plasma-derived medicines and a forerunner in the research and development of therapeutic alternatives that drive scientific and social progress, today announced a new collaboration agreement with IrsiCaixa AIDS Research Institute.

Under the agreement, Grifols will finance current and future research lines to advance the search for new treatments for HIV/AIDS and associated diseases, such as infectious, oncological, neurodegenerative and age-related conditions. The accord will also enable IrsiCaixa to address other critical challenges in the biomedical field, including the study of the human microbiome and emerging infectious diseases, and leverage its accumulated knowledge on HIV/AIDS and resultant immune disorder. In alignment with its longstanding dedication to innovation, Grifols will contribute EUR 1.5 million per year over the next five years to support these efforts.

IrsiCaixa is a private non-profit foundation established in 1995 by "la Caixa" Banking Foundation and the Ministry of Health of the Government of Catalonia. For more than 20 years, it has headed research to eradicate HIV/AIDS and associated diseases. Its unique model for collaboration fosters the transfer of knowledge among key stakeholders in the fight against HIV/AIDS and advances the search for new solutions to treat and eradicate the disease.

As a result of this collaboration agreement, Grifols is now one of two preferential financial partners chosen to fund IrsiCaixa's new research lines, together with "la Caixa" Banking Foundation. In addition to financing rights, the accord grants Grifols preference to exploit the results and patents stemming from IrsiCaixa's diverse research initiatives. Nonetheless, IrsiCaixa will retain exclusive ownership and the rights to use results for in-house research initiatives.

A follow-up committee will meet periodically to assess the progress of IrsiCaixa's research projects. Committee members will include representatives from Grifols and IrsiCaixa, including Bonaventura Clotet, the director of IrsiCaixa, president of the Fight AIDS Foundation, and head of the Infectious Diseases Unit at Germans Trias i Pujol University Hospital.

The collaboration agreement was signed through Grifols Innovation and New Technologies (GIANT), responsible for channeling the group's investments in R+D companies and research initiatives.

## About IrsiCaixa

The [IrsiCaixa](#) AIDS Research Institute was founded in 1995 by l'Obra Social "la Caixa" and the Catalanian Government Ministry of Health to promote research on HIV/AIDS and associated diseases. IrsiCaixa is located in Germans Trias i Pujol University Hospital in Badalona (Barcelona). The center has over 75 professionals dedicated to scientific research, education and dissemination and collaborates with more than 3,000 patients and healthcare professionals at the hospital's Infectious Diseases Unit. The institute's current strategic lines include complementary research on immune system conditions, such as intestinal microbiome, cancer, neurodegenerative conditions and emerging infectious conditions.

## About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols' three main divisions -Bioscience, Diagnostic and Hospital- develop, produce and market innovative products and services that are available in more than 100 countries.

Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries. In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit [www.grifols.com](http://www.grifols.com)

## "la Caixa" Banking Foundation: more than 30 years promoting research

"la Caixa" Banking Foundation has been promoting research of excellence for more than 30 years. Over the course of the last three decades, the Foundation has devoted more than 400 million euros to 490 research projects; founded IrsiCaixa (1995), in cooperation with the Catalan Government; awarded 4,771 excellence scholarships to promote the training of young people at around one hundred Spanish universities and research centres; funded 1,700 clinical trials of new treatments for patients with cancer, AIDS, malaria, etc.; and launched a new call for proposals for biomedical research projects in Spain and Portugal.

Looking to the future, "la Caixa" Banking Foundation's commitment to promoting people's health and wellbeing continues, and the 2016-2019 Strategic Plan 2016-2019 intensifies this support by tripling the budget devoted to research, taking it to 90 million euros in 2019. As a result, the overall budget will increase to 520 million euros this year, an effort that makes the Foundation the second-most important in Europe and the third in the world in terms of philanthropy.

### Press Contacts:

#### Grifols Press Office

Raquel Lumbreras [raquel\\_lumbreras@duomocomunicacion.com](mailto:raquel_lumbreras@duomocomunicacion.com)

Borja Gómez [borja\\_gomez@duomocomunicacion.com](mailto:borja_gomez@duomocomunicacion.com)

Phone: +34 91 311 92 89 - 91 311 92 90

[www.grifols.com](http://www.grifols.com)

#### IrsiCaixa Communications

Júlia Bestard – Phone: +34 93 465 63 74 ext. 121 [comunicacio@irsicaixa.es](mailto:comunicacio@irsicaixa.es)

[www.irsicaixa.es](http://www.irsicaixa.es) | [@IrsiCaixa](https://twitter.com/IrsiCaixa)

#### "la Caixa" Banking Foundation

Irene Roch. Phone: +34 93 404 60 27 [iroch@fundaciolacaixa.es](mailto:iroch@fundaciolacaixa.es)

[www.lacaixa.es/obrasocial](http://www.lacaixa.es/obrasocial)